Search published articles


Showing 2 results for Adipose Tissue

Seyyed Manuchehr Nourazarian , Mojtaba Ghaffarian , Homayun Dolatkhah ,
Volume 10, Issue 3 (5-2016)
Abstract

ABSTRACT

        Background and Objective: The relationship between diabetes mellitus and increased risk of cardiovascular diseases has been demonstrated. The aim of this study was to determine the fatty acid profile of epicardial adipose tissue in diabetic and non-diabetic patients with cardiovascular disease.

         Methods: In this study, 28 diabetic and 40 nondiabetic patients were evaluated. The epicardial adipose tissue and blood samples of patients were collected during surgery. Non‐esterified fatty acids and phospholipids were measured by the thin layer chromatography and gas chromatography.

         Results:  Saturated free fatty acids (12: 0) level was higher in diabetic patients compared to nondiabetic patients (P=0.038), while saturated free fatty acids (16: 0) was significantly lower in diabetics (P=0.011). Unsaturated fatty acid (20: 3n-9) was higher in nondiabetics compared to  diabetics (P=0.015). There was a significant decrease in level of monounsaturated fatty acids in diabetic patients. The epicardial adipose tissue of diabetics showed a significant increase in free fatty acid (18: 0) and conjugated linoleic acid levels, while there was a significant decrease in the level of free fatty acid (18: 1n-11). Level of epicardial omega-3 free fatty acid (20: 5 n-3) and 22: 6 n -3 was significantly reduced in these patients.

         Conclusion: Differences in the serum free fatty acid profile of the two groups may be due to differences in their diet, while changes in the fatty acid composition of epicardial adipose tissue in these two groups could be due to impaired metabolism of fatty acids such as uptake, movement and androgen synthesis as a result of diabetes. These changes increase the risk of developing atherosclerosis in diabetic patients.

       


Mehdi Nasiraey, Abdolreza Jafari Chashmi, Seyd Abdollah Hashemvarzi,
Volume 14, Issue 6 (11-2020)
Abstract

Background and objectives: It has been suggested that irisin and fibronectin type III domain-containing protein 5 (FNDC5) can increase energy expenditure, promote weight loss and improve insulin resistance in diabetic patients by affecting white and brown adipose tissues. In this study, we investigate effect of adipose tissue-derived stem cell transplantation and six weeks of aerobic exercise on FNDC5 and irisin levels in streptozotocin-induced diabetic rats.
Methods: Forty-eight rats (weighing 220-240 g and aged nine weeks) were divided into six groups of control, sham, diabetes control, diabetes + exercise, diabetes + stem cell and diabetes+ exercise + stem cell. The exercise group ran on running wheel at intensity of 60-70% VO2max, five days a week for six weeks. Next, 1.56 × 106 stem cells extracted from human adipose tissue were injected into the tail vein of streptozotocin-induced diabetic rats. Finally, FNDC5 and irisin plasma levels of the mice were measured using enzyme-linked immunosorbent assay kits.  
Results: FNDC5 and irisin levels reduced significantly in the diabetes control group (P=0.0001). FNDC5 levels in the diabetes + exercise + stem cell and the exercise group increased significantly compared to the diabetes control group (P=0.0001). The irisin level in the diabetes + stem cell + exercise group, exercise group and stem cell group increased significantly compared to the diabetes control group (P=0.0001).  
Conclusion: The results indicate that aerobic exercise program and stem cell therapy alone and combined can significantly increase plasma irisin levels. Given the favorable effects of adipose tissue-derived stem cell injection and aerobic exercise on FNDC5 and irisin levels, this strategy could be further evaluated in coping with the adverse effects of diabetes on metabolism and aging

Page 1 from 1     

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.